Premium
Sustained response to intrathecal rituximab in EBV associated Post‐transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant
Author(s) -
Bonney Denise K.,
Htwe Ei E.,
Turner Andrew,
Kelsey Anna,
Shabani Abdu,
Hughes Stephen,
Hughes Imelda,
Wynn Robert F.
Publication year - 2012
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.23134
Subject(s) - medicine , rituximab , haematopoiesis , stem cell , lymphoma , central nervous system , hematopoietic stem cell transplantation , lymphoproliferative disorders , post transplant lymphoproliferative disorder , immunology , chemotherapy , intrathecal , complication , blood cancer , hematopoietic stem cell , disease , oncology , immunosuppression , cancer , surgery , biology , genetics
Post‐transplant lymphoproliferative disorder (PTLD) in the central nervous system (CNS) is a very rare complication of haematopoietic stem cell transplant (HSCT) and has a dismal prognosis. We report the successful treatment of this disorder with intrathecal rituximab therapy in two children who developed isolated CNS PTLD after HSCT. These children had failed to respond to standard chemotherapy, intravenous rituximab and EBV specific cellular therapy. Pediatr Blood Cancer 2012; 58: 459–461. © 2011 Wiley Periodicals, Inc.